Motor and nonmotor heterogeneity of LRRK2‐related and idiopathic Parkinson's disease

Parkinson's disease (PD) associated with LRRK2 mutations has been described as similar to idiopathic PD with minor clinical differences. No study has compared the clinical features of LRRK2‐associated PD due to different mutations. The objective of this study was to compare LRRK2‐associated PD due to G2019S and G2385R mutations and to compare each to idiopathic PD.

[1]  J. Allen,et al.  Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants , 2015, Neurology.

[2]  K. Marder,et al.  REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers , 2015, Movement disorders : official journal of the Movement Disorder Society.

[3]  E. Tolosa,et al.  Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers , 2015, PloS one.

[4]  G. Rouleau,et al.  LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. , 2015, Parkinsonism & related disorders.

[5]  T. Montine,et al.  Cognitive profile of LRRK2‐related Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[6]  E. Tolosa,et al.  Nonmotor Symptoms in LRRK2 G2019S Associated Parkinson’s Disease , 2014, PloS one.

[7]  K. Marder,et al.  Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker? , 2014, Annals of clinical and translational neurology.

[8]  E. Tolosa,et al.  Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants , 2014, Genetics in Medicine.

[9]  K. Johansen,et al.  Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers , 2014, Acta neurologica Scandinavica.

[10]  J. Trinh,et al.  A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism , 2014, Neurobiology of Aging.

[11]  K. Marder,et al.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. , 2014, Parkinsonism & related disorders.

[12]  P. Chan,et al.  Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals , 2014, Neurobiology of Aging.

[13]  P. Mazzoni,et al.  Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[14]  J. Zarranz,et al.  Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. , 2013, Parkinsonism & related disorders.

[15]  Xiao-Guang Luo,et al.  LRRK2 G2385R variant carriers of female Parkinson’s disease are more susceptible to motor fluctuation , 2013, Journal of Neurology.

[16]  J. Molinuevo,et al.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study , 2013, The Lancet Neurology.

[17]  J. Jankovic,et al.  How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale , 2013, Movement disorders : official journal of the Movement Disorder Society.

[18]  G. Stebbins,et al.  Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scores , 2012, Movement disorders : official journal of the Movement Disorder Society.

[19]  U. Klose,et al.  Clinical and brain imaging characteristics in leucine‐rich repeat kinase 2–associated PD and asymptomatic mutation carriers , 2011, Movement disorders : official journal of the Movement Disorder Society.

[20]  A. López de Munain,et al.  Olfactory deficits and cardiac 123I‐MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations , 2011, Movement disorders : official journal of the Movement Disorder Society.

[21]  A. Lang,et al.  Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers , 2011, Neurology.

[22]  E. Tolosa,et al.  123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations , 2011, Journal of Neurology.

[23]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[24]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[25]  Bart Post,et al.  UvA-DARE ( Digital Academic Repository ) Clinimetrics , clinical profile and prognosis in early Parkinson ’ s disease , 2009 .

[26]  A. Destée,et al.  LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. , 2007, Archives of neurology.

[27]  C. Mariani,et al.  LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. , 2006, Parkinsonism & related disorders.

[28]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[29]  M. Farrer,et al.  Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. , 2005, Parkinsonism & related disorders.

[30]  Mathias Toft,et al.  Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.

[31]  Tatiana Foroud,et al.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.

[32]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[33]  P. Kolatkar,et al.  The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence , 2006, Human Genetics.